Corporate Overview

History

Since 2001, Tracera has been dedicated to the development, commercialization and support of automated radiopharmaceutical synthesis instrumentation for imaging agent production.

Tracera developed a number of different synthesis modules such as the Fluorobromomethane (FBM) Module and the Fluoromethylation (FMethyl) Module. Concurrent to Tracera’s initial offerings, there was a surge in radiopharmaceutical research centered on new PET Tracers. With researchers and producers of novel tracers spending time and effort customizing existing hardware to deal with more complex chemistries, Tracera realized a need for a complete, automated and flexible hardware solution to deal with the increasing complexity. Thus, Tracera began development of what was to become the TS-1.

Tracera has been successful in its pursuit of a solution to the pains associated with complex chemistries. The culmination of the development efforts, the TS-1, is a best-in-class radiochemistry synthesis module. Launched in 2007, the TS-1 offers both the PET researcher and the nuclear pharmacist a means to efficiently incorporate complex radiochemistry syntheses into their work.